Neutrolin Usage Monitoring Program (NUMP)

Neutrolin® prevents thrombosis

Neutrolin® effectively protects dialysis efficiency, because thrombosis and clotting is reliably prevented.1

Active ingredient combination heparin and citrate (3.5 %)

  • Anticoagulant prevents clotting
  • Optimal citrate concentration of 3.5 % (acc. to FDA recommendation max. 4 %)
  • Combination prevents thrombosis significantly better than required by international guidelines
  • Considerable reduction of urokinase treatment
*Journeycake et al., JCO 2006

Neutrolin® shields against infections

Neutrolin® effectively protects dialysis efficiency, because HD patients are shielded from infections.1

  • Decrease of inflammation parameters (e.g. hs-CRP, IL-6)6
  • Protects reliably against catheter-related bloodstream infections (CRBSI)
  • Works also against resistant germs e.g. MRSA or VRE7
** CDC Guidelines for the Prevention of Intravascular Catheter Related Infections; O`Grady et al., 2011

Infection risk with central venous catheters (CVC)

  • Catheter-related bloodstream infections (CRBSI) are one of the major causes of healthcare-associated bloodstream infections8
  • CVCs increase the infection-related mortality in hemodialysis patients 2–3-fold9
  • CVCs show a 15–20 times higher infection risk compared to shunts10

Neutrolin® preserves blood flow

Neutrolin® effectively protects dialysis efficiency, because blood flow is preserved. Current research (>7,700 catheter days) shows excellent results:1

  • Additional treatment costs are reduced (no partial catheter blocks)
  • Reliable treatment schedules by means of predicable blood flow
*** Vascular Access Work Group, “Clinical practice guidelines for vascular access” 2006

Sales representant request

Download instructions of use

Download information for dialysis efficiency

1) Cormedix data on file, Neutrolin Use Monitoring Program, Stand Nov. 2014. 2) Passerini, L. et al., Crit. Care Med. 1992. 3) Ramanathan, V. et al., AJKD 2012. 4) Hörl, W.H., Spektrum der Nephrologie 2/2013. 5) Raad, I., Lancet 1998. 6) Fontseré, N. et al., Antimicrob. Agents Chemother. 2014. 7) Torres-Viera, C. et al., Antimicrobial Agents and Chemotherapy 2000. 8) O´Grady, N.P. et al., MMWR Recomm. Rep. 2002. 9) Pastan, S. et al., Kidney Int. 2002; Polkinghorne, K.R. et al., Clin. J. Am. Soc. Nephrol. 2004. 10) Vascular Access Work Group. AJKD 2006, 48 Suppl. 1. 11) Blot, S.I. et al., Clin. Infect. Dis. 2005. 12) Orsi, G.B. et al., Infect. Control Hosp. Epidemiol. 2002.
13) Graphics modified from Quarello, F. at al., Blood Purif. 2002; 20: 87-92